Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Albertini

Showing results (171-180 of 221) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsM R Albertini, J A Hank, J H Schiller, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|March 26, 2010
Serum IGF-I and IGFBP-3 reference values from a chemiluminescent assay in normal children and adolescents of hispanic and italian origin: presence of sexual dimorphism in IGF-I valuesE A Chaler, C Meazza, G Guercio, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2012
Phase II trial of hu14.18-IL2 for patients with metastatic melanomaMark R Albertini, Jacquelyn A Hank, Brian Gadbaw, et al.
Inflammation|April 19, 2008
Low level laser therapy (LLLT) decreases pulmonary microvascular leakage, neutrophil influx and IL-1beta levels in airway and lung from rat subjected to LPS-induced inflammationF Aimbire, A P Ligeiro de Oliveira, R Albertini, et al.
Photomedicine and Laser Surgery|May 19, 2007
Effect of low-level laser therapy on hemorrhagic lesions induced by immune complex in rat lungsF Aimbire, R A B Lopes-Martins, R Albertini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB studyJ H Schiller, J A Hank, M Khorsand, et al.
Journal of Inorganic Biochemistry|April 1, 1996
Synthesis, structure, and spectroscopic properties of acetato(dimethyl)(pyridine-2-carbaldehydethiosemicarbazonato)tin(IV) acetic acid solvate, [SnMe2(PyTSC)(OAc)].HOAc. Comparison of its biological activity with that of some structurally related diorganotin(IV) bis(thiosemicarbazonates)J S Casas, M S García-Tasende, C Maichle-Mössmer, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanomaM R Albertini, J Gan, P Jaeger, et al.
Inflammation|March 17, 2021
The MAPKinase Signaling and the Stimulatory Protein-1 (Sp1) Transcription Factor Are Involved in the Phototherapy Effect on Cytokines Secretion from Human Bronchial Epithelial Cells Stimulated with Cigarette Smoke ExtractA Brito, T Santos, K Herculano, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1993
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancerC Gambacorti-Passerini, J A Hank, M R Albertini, et al.
Pageof 23

Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsM R Albertini, J A Hank, J H Schiller, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|March 26, 2010
Serum IGF-I and IGFBP-3 reference values from a chemiluminescent assay in normal children and adolescents of hispanic and italian origin: presence of sexual dimorphism in IGF-I valuesE A Chaler, C Meazza, G Guercio, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2012
Phase II trial of hu14.18-IL2 for patients with metastatic melanomaMark R Albertini, Jacquelyn A Hank, Brian Gadbaw, et al.
Inflammation|April 19, 2008
Low level laser therapy (LLLT) decreases pulmonary microvascular leakage, neutrophil influx and IL-1beta levels in airway and lung from rat subjected to LPS-induced inflammationF Aimbire, A P Ligeiro de Oliveira, R Albertini, et al.
Photomedicine and Laser Surgery|May 19, 2007
Effect of low-level laser therapy on hemorrhagic lesions induced by immune complex in rat lungsF Aimbire, R A B Lopes-Martins, R Albertini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB studyJ H Schiller, J A Hank, M Khorsand, et al.
Journal of Inorganic Biochemistry|April 1, 1996
Synthesis, structure, and spectroscopic properties of acetato(dimethyl)(pyridine-2-carbaldehydethiosemicarbazonato)tin(IV) acetic acid solvate, [SnMe2(PyTSC)(OAc)].HOAc. Comparison of its biological activity with that of some structurally related diorganotin(IV) bis(thiosemicarbazonates)J S Casas, M S García-Tasende, C Maichle-Mössmer, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanomaM R Albertini, J Gan, P Jaeger, et al.
Inflammation|March 17, 2021
The MAPKinase Signaling and the Stimulatory Protein-1 (Sp1) Transcription Factor Are Involved in the Phototherapy Effect on Cytokines Secretion from Human Bronchial Epithelial Cells Stimulated with Cigarette Smoke ExtractA Brito, T Santos, K Herculano, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1993
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancerC Gambacorti-Passerini, J A Hank, M R Albertini, et al.
Pageof 23